Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance of [14C]DA-302168S in Healthy Adult Male Trial Participants in China
NCT07857265Phase 1Not yet recruiting
- Sponsor
- Chengdu Diao Pharmaceutical Group
- Start
- Nov 2026
- Primary completion
- Dec 2026
01
Overview
Phase 1, open-label, single-arm trial of DA-302168S in type 2 diabetes mellitus (T2DM) and obesity, sponsored by Chengdu Diao Pharmaceutical Group. Primary endpoint: Total recovery of DA-302168S radioactivity in urine and feces at Day 8. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
DA-302168S
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT07857265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07857265.